Microbot Medical Inc. (MBOT)
After hours:
| Previous close | 0.9528 |
| Open | 0.9700 |
| Bid | 0.8786 x 100 |
| Ask | 0.9449 x 100 |
| Day's range | 0.9105 - 0.9700 |
| 52-week range | 0.8600 - 4.3700 |
| Volume | |
| Avg. volume | 97,203 |
| Market cap | 13.11M |
| Beta (5Y monthly) | 1.65 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Microbot Medical Announces Positive Results from the First Phase of its Collaboration with Corewell Health™
The next step of the collaboration will explore potential future applications of the LIBERTY system, including its potential capabilities for remote endovascular proceduresBRAINTREE, Mass., April 29, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today reports that the first phase of the previously announced collaboration with Corewell Health has been completed, which demonstrated the LIBERTY® System's tec
- GlobeNewswire
Microbot Medical Shares Status Following Recent Geopolitical Events
All Regulatory, Clinical, Operational and Pre-Commercial Activities Continue to Stay on Track Despite the On-going Situation in Israel Company Believes that Both Regulatory and Commercial Milestones to be Achieved in Accordance with the Company’s Current Timeline BRAINTREE, Mass., April 15, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the LIBERTY® Endovascular Robotic Surgical System, today shared that despite the unprecedented events in Israel yesterday, which are
- GlobeNewswire
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
The Investigational Device Exemption (IDE) application follows the completion of multiple activities necessary to file this applicationBRAINTREE, Mass., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the LIBERTY® Endovascular Robotic Surgical System, announced that it has filed an Investigational Device Exemption (IDE) application with the US Food and Drug Administration (FDA). The IDE application follows the completion of multiple preclinical activities per
